青光眼长期视野进展的点式测量方法比较
该回顾性观察性队列研究纳入729只眼(567例原发性开角型青光眼患者),比较GPA、PLR和GRI三种点式方法估计视野进展速率。结果显示GRI标记的进展眼比例最高(52.9%),检测进展的中位时间最短(8.8年),提示GRI能更早检测长期视野进展。
要点
- GRI标记进展眼比例(52.9%)高于PLR(33.5%)和GPA(27.7%)。
- GRI检测进展的中位时间最短(8.8年),GPA和PLR均超过16年。
- 在可能进展亚组中,GRI仍标记最高比例(92.9%)的进展眼。
核心结论
- GRI可能比PLR或GPA更早检测青光眼长期视野进展。
- 需前瞻性研究验证以增强该方法的普遍性和价值。
研究设计与样本
- 回顾性观察性队列研究,纳入729只眼(567例原发性开角型青光眼患者),至少6次可靠视野和至少3年随访。
- 数据收集于1988年5月至2004年11月,分析于2018年10月至2019年2月。
主要发现
- 标记为进展的眼比例:GPA 27.7%,PLR 33.5%,GRI 52.9%。
- GRI vs PLR差异20%(95%CI 17%-23%),GRI vs GPA差异25%(95%CI 22%-29%),PLR vs GPA差异6%(95%CI 3%-9%),所有比较P<.001(McNemar检验)。
- 检测进展的中位时间:GRI 8.8年(IQR 2.4-10.5年),GPA和PLR均>16年。
- GRI vs PLR(参照)的进展风险比11.3(95%CI 9.2-13.7),GRI vs GPA(参照)18.1(95%CI 14.5-22.6),PLR vs GPA(参照)1.5(95%CI 1.3-1.9),所有比较P<.001(Cox比例风险回归)。
- 在可能进展亚组中,进展眼比例:GPA 73.7%(115/156),PLR 81.4%(127/156),GRI 92.9%(145/156)。
关键数值与推荐
- 基线平均偏差中位数-6.7 dB(IQR -11.6至-3.5 dB),随访时间中位数8.9年(IQR 7.3-10.4年)。
- 患者平均年龄65.6岁(SD 9.7),女性300例(52.9%),白人295例(52.0%)。
临床怎么用
- GRI可能有助于更早识别青光眼视野进展,从而对快速进展者及时加强治疗、对低风险者避免过度治疗。
局限性
- 回顾性研究设计,需前瞻性验证以增强普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Rates of visual field (VF) progression vary among patients with glaucoma. Knowing the rate of progression of individual patients would allow appropriately aggressive therapy for patients with high rates of visual loss and protect those with low rates from unnecessary therapy. OBJECTIVE: To compare 3 pointwise methods of estimating the rate of VF progression in glaucoma. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, observational cohort study included 729 eyes of 567 consecutive patients with primary open-angle glaucoma who had at least 6 reliable VFs and at least 3 years of follow-up. One hundred seventy-six patients (257 eyes) were treated at a tertiary glaucoma center; in addition, data were collected from 391 participants (472 eyes) in the Advanced Glaucoma Intervention Study. Data were collected from May 1988 to November 2004 and analyzed from October 2018 to February 2019. EXPOSURES: Estimates of VF progression were measured with guided progression analysis (GPA), pointwise linear regression (PLR), and the glaucoma rate index (GRI). A subgroup analysis was performed in a subset of patients with likely VF progression and likely VF stability. MAIN OUTCOMES AND MEASURES: Proportion of VF series detected as progressing, estimates of false-positive proportions, time to detect progression, and agreement among measures. RESULTS: Among the 567 patients included in the analysis, mean (SD) age was 65.6 (9.7) years, 300 (52.9%) were female, and 295 (52.0%) were white. The median baseline mean deviation was -6.7 (interquartile range [IQR], -11.6 to -3.5) dB; the median follow-up time, 8.9 (IQR, 7.3-10.4) years. The proportion of eyes labeled as progressing was 27.7% according to the GPA, 33.5% according to the PLR, and 52.9% according to the GRI; pairwise differences for GRI vs PLR were 20% (95% CI, 17%-23%); for GRI vs GPA, 25% (95% CI, 22%-29%); and for PLR vs GPA, 6% (95% CI, 3%-9%; P < .001 for all comparisons, McNemar test). The shortest median time to progression was with the GRI (8.8 [IQR, 2.4-10.5 years), compared with the GPA and PLR (both >16 years). The hazard ratio of VF progression for GRI vs PLR (reference) was 11.3 (95% CI, 9.2-13.7); for GRI vs GPA (reference), 18.1 (95% CI, 14.5-22.6); and for PLR vs GPA (reference), 1.5 (95% CI, 1.3-1.9; P < .001 for all comparisons, Cox proportional hazards regression). These results held in the subgroup with likely progression; the proportions of progressing eyes were 73.7% (115 of 156) for GPA, 81.4% (127 of 156) for PLR, and 92.9% (145 of 156) for GRI. Pairwise difference for GRI vs PLR was 11.5% (95% CI, 7.4%-17.6%; P < .001, McNemar test); for GRI vs GPA, 19.2% (95% CI, 12.6%-26.4%; P < .001, McNemar test); and for PLR vs GPA, 7.7% (95% CI, 0.3%-15.7%; P = .08, McNemar test). CONCLUSIONS AND RELEVANCE: These results suggest GRI can detect long-term VF progression in glaucoma earlier than PLR or GPA. Validation with prospective designs may strengthen the generalizability and value of this method.
引用
- Salazar D, Morales E, Rabiolo A, et al. Pointwise Methods to Measure Long-term Visual Field Progression in Glaucoma. JAMA Ophthalmol. 2020. PMID: 32239185. doi:10.1001/jamaophthalmol.2020.0647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。